Login to Your Account

ECYT Shares Ride the Wave of Enthusiasm, Up 100%

Endocyte May Get Up to $1B from Merck for Cancer Drug

By Marie Powers
Staff Writer

Tuesday, April 17, 2012
After being drubbed in December 2011 following inconclusive data from a Phase IIb study, Endocyte Inc.'s cancer drug EC145 (vintafolide) made a 180-degree turn, attracting a potential $1 billion deal with Merck & Co. Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription